ClinicalTrials.gg

Program

Methoxydimethyltryptamines

Also written as “5 Methoxy N,N Dimethyltryptamine”, “GH001” and “BMND08”.

Its studies are mostly in Depressive Disorder, Treatment-Resistant · Mood Disorders · Depression, Postpartum · Bipolar Disorder, led by 3 companies.

Furthest: phase 2, since Nov 17, 202011 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GH Research Ireland90 open or runningphase 2since Nov 17, 2020Nov 12, 2020none ahead
Biomind Labs10 open or runningphase 2since Dec 10, 2024Dec 10, 2024none ahead
Eli Lilly10 open or runningphase 1since Aug 24, 2021Aug 24, 2021none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2020First study: phase 1 study in Healthy VolunteersNew to GH Research IrelandGH Research Ireland · NCT04640831 · 22 enrolled · Netherlands
  2. Nov 17, 2020Phase 2 study in Depressive Disorder, Treatment-ResistantGH Research Ireland · NCT04698603 · 16 enrolled · Netherlands
  3. Aug 24, 2021Eli Lilly's first study: phase 1 study in Pharmacokinetics in Healthy AdultsNew to Eli LillyEli Lilly · NCT05032833 · 36 enrolled · United Kingdom
  4. Nov 18, 2021Phase 1 study in Healthy VolunteersGH Research Ireland · NCT05163691 · 46 enrolled · Netherlands
  5. Feb 23, 2023Phase 1 study in Healthy VolunteersGH Research Ireland · NCT05753956 · 64 enrolled · Netherlands
  6. Mar 22, 20232 phase 2 studiesGH Research Ireland · NCT05800860, NCT05804708
  7. Apr 20, 2023Phase 2 study in Bipolar DisorderGH Research Ireland · NCT05839509 · 6 enrolled · Germany, Netherlands, United Kingdom
  8. Jun 28, 2024Phase 1 study in Healthy VolunteersGH Research Ireland · NCT06511947 · 71 enrolled · United Kingdom
  9. Dec 10, 2024Biomind Labs's first study: phase 2 study in Mood DisordersNew to Biomind LabsBiomind Labs · NCT06816667 · 40 enrolled · Argentina
  10. Apr 1, 2026Phase 1 study in Healthy AdultGH Research Ireland · NCT07540494 · 13 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 11 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07540494Healthy Adult · United States1CompletedGH Research IrelandMay 8, 202613
NCT06816667Mood Disorders · Argentina2CompletedBiomind LabsFeb 14, 202540
NCT06511947Healthy Volunteers · United Kingdom1TerminatedGH Research IrelandMar 23, 202671
NCT05839509Bipolar Disorder · Germany, Netherlands, United Kingdom2TerminatedGH Research IrelandNov 13, 20246
NCT05804708Depression, Postpartum · Netherlands, United Kingdom2TerminatedGH Research IrelandAug 2, 202410
NCT05800860Depressive Disorder, Treatment-Resistant · Czechia, Germany, Ireland and more2CompletedGH Research IrelandOct 4, 202481
NCT05753956Healthy Volunteers · Netherlands1CompletedGH Research IrelandNov 29, 202364
NCT05163691Healthy Volunteers · Netherlands1CompletedGH Research IrelandOct 23, 202146
NCT05032833Pharmacokinetics in Healthy Adults · United Kingdom1CompletedEli LillyJul 7, 202236
NCT04698603Depressive Disorder, Treatment-Resistant · Netherlands2CompletedGH Research IrelandNov 6, 202116
NCT04640831Healthy Volunteers · Netherlands1CompletedGH Research IrelandOct 4, 201922

How it is read

Names in the registry

  • “5 Methoxy N,N Dimethyltryptamine”, 6 entries
  • “GH001”, 3 entries
  • “BMND08”, 1 entry
  • “5-MeO-DMT”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.